High-dose Cephalexin for Cellulitis (HI-DOCC) (HI-DOCC)
Cellulitis
About this trial
This is an interventional treatment trial for Cellulitis focused on measuring Cellulitis, Cephalexin, Oral antibiotics, Treatment failure
Eligibility Criteria
Inclusion Criteria: Adults (age ≥18 years) diagnosed with non-purulent cellulitis and determined by the treating emergency physician to be eligible for outpatient oral antibiotics. Exclusion Criteria: Age <18 years; Patient already taking oral antibiotics; Treating physician decides IV antibiotics are required; Abscess requiring an incision and drainage procedure; Known prior cellulitis secondary to methicillin-resistant Staphylococcus aureus (MRSA); Cellulitis secondary to a human or animal bite wound; Penetrating wound or water exposure resulting in cellulitis; Surgical site infection; Patient found at a follow up visit to have an alternative, non-infectious etiology (e.g., deep vein thrombosis); bilateral symptoms (e.g., both legs involved); Malignancy and currently being treated with chemotherapy; Solid organ or bone marrow transplant recipient; Renal impairment with an estimated glomerular filtration rate <30 mL/min documented on the health record at any time within the past three months; Allergy to cephalosporins or history of anaphylaxis to penicillin; Inability to provide informed consent
Sites / Locations
- The Ottawa HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
High Dose Cephalexin
Standard Dose Cephalexin
The intervention is high-dose cephalexin (1000mg PO QID) for seven days
The comparator is standard-dose cephalexin (500mg PO QID) plus oral placebo for seven days